1. Latar belakang klinis
Gambaran penyakit
Uraian berikut tersedia dalam bahasa Inggris.
Non-small-cell lung cancer (NSCLC) accounts for roughly 80-85% of all lung cancers, with adenocarcinoma the dominant histology, and is most often diagnosed at locally advanced or metastatic stages when cure is no longer feasible. A clinically important molecular subset is driven by activating mutations in the epidermal growth factor receptor (EGFR) gene, most commonly exon 19 deletions and the exon 21 L858R substitution, which render tumours oncogenically dependent on constitutive EGFR tyrosine-kinase signalling and confer marked sensitivity to oral EGFR tyrosine-kinase inhibitors (TKIs) rather than to cytotoxic chemotherapy. These tumours characteristically arise in never-smokers, women and patients of East and Southeast Asian ancestry, and show a strong propensity for central nervous system (CNS) metastasis. Progression on first-generation TKIs is commonly mediated by the acquired T790M gatekeeper mutation. Osimertinib is a third-generation, irreversible EGFR-TKI that inhibits both sensitising mutations and T790M while penetrating the blood-brain barrier (Soria 2018; Ramalingam 2020).
Epidemiologi
Uraian berikut tersedia dalam bahasa Inggris.
Lung cancer (ICD-10 C33-C34) was the most commonly diagnosed cancer and the leading cause of cancer death worldwide in 2022, with an estimated 2,480,675 new cases and 1,817,469 deaths, about 18.7% of all cancer mortality (GLOBOCAN 2022; Bray 2024; Leiter 2024). In Indonesia, GLOBOCAN 2022 estimated 38,904 new lung cancer cases (roughly 9.5% of the country's 408,661 cancers) and 34,339 lung cancer deaths, making it the leading cause of cancer death nationally, against a national total of 242,099 cancer deaths (GLOBOCAN 2022, Indonesia fact sheet). The EGFR-mutant fraction is disproportionately large in this population: a national audit of 1,874 newly diagnosed Indonesian patients detected EGFR mutations in 44.5% (95% CI 42.1-46.7), reaching 52.9% in women versus 39.1% in men (Syahruddin 2018), roughly threefold higher than Western cohorts (10-15%) and consistent with the broader regional figure of 49.3% reported in Asia-Pacific adenocarcinoma (IGNITE; Han 2017).
Terapi standar saat ini
Uraian berikut tersedia dalam bahasa Inggris.
Internationally, osimertinib monotherapy is the preferred first-line standard for EGFR exon 19 deletion or L858R advanced NSCLC, supported by NICE, ESMO and NCCN, with first-generation (gefitinib, erlotinib) and second-generation (afatinib, dacomitinib) TKIs as alternatives where osimertinib is unavailable. In Indonesia, real-world first-line practice under JKN/BPJS still leans heavily on first- and second-generation TKIs: a 14-centre Indonesian cohort of EGFR-positive patients with advanced lung adenocarcinoma documented widespread first-line afatinib use, with a median progression-free survival of about 12 months (Suryani 2025), and osimertinib has been positioned chiefly as a second-line option after T790M-confirmed progression. Limitations of the first-generation comparators are well established: shorter progression-free survival (about 10 months), inferior CNS control, near-universal acquired resistance, and dose-limiting skin and gastrointestinal toxicity. Reliance on sequencing assumes successful re-biopsy and timely T790M testing, which is not reliably achievable across the Indonesian health system, leaving a gap between local reimbursed practice and the global guideline-preferred therapy.
Status regulasi dan penjaminan
Uraian berikut tersedia dalam bahasa Inggris.
Osimertinib (Tagrisso, AstraZeneca; ATC L01EB04) received US FDA accelerated approval in 2015 for T790M-positive disease and first-line approval on 18 April 2018 for metastatic EGFR exon 19 deletion or L858R NSCLC; EMA/European Commission approval followed in 2016 with the first-line extension granted in 2018 (FDA 2018; EMA Tagrisso EPAR). In England, NICE recommended first-line osimertinib in technology appraisal TA654, published 14 October 2020 (which updated and replaced TA621), contingent on a confidential commercial discount (NICE TA654 2020). In Indonesia, osimertinib is registered with BPOM but reimbursement under Jaminan Kesehatan Nasional is the decisive access barrier: National Formulary (Fornas) listing and InaHTAC cost-effectiveness review are required before a BPOM-approved oncology drug is funded under JKN, and osimertinib has historically been restricted to the T790M-positive second-line setting rather than first line (Wibawa 2024; Suryani 2025). The precise current restriction should be verified against the e-Fornas listing (e-fornas.kemkes.go.id) before finalising any reimbursement assumption.
2. Hasil kasus dasar
| Strategi | Biaya terdiskonto | QALY terdiskonto | Tahun hidup |
|---|---|---|---|
| Osimertinib 80 mg sekali sehari | Rp 538,2 juta | 3,672 | 5,68 |
| penghambat tirosin kinase EGFR generasi terdahulu (afatinib, gefitinib, atau erlotinib) | Rp 402,8 juta | 2,693 | 4,07 |
| Selisih | Rp 135,4 juta | 0,979 | - |
3. Analisis probabilistik
- Simulasi probabilistik (500 sampel)
- Kasus dasar
4. Analisis sensitivitas
- Parameter pada nilai rendah
- Parameter pada nilai tinggi
5. Analisis skenario
| Skenario | Selisih QALY | Selisih biaya | Rasio per QALY |
|---|---|---|---|
| Base case (20 yr) | 0,979 | Rp 135,4 juta | Rp 138,3 juta |
| 5-year horizon | 0,411 | Rp 75,2 juta | Rp 183,0 juta |
| 10-year horizon | 0,851 | Rp 119,7 juta | Rp 140,7 juta |
| 0% discount rate | 1,201 | Rp 157,8 juta | Rp 131,3 juta |
| 5% discount rate | 0,861 | Rp 123,7 juta | Rp 143,6 juta |
| Undiscounted list price (Rp 516M/yr, no commercial arrangement) | 0,979 | Rp 385,9 juta | Rp 394,2 juta |
| Lower real-world OS benefit (osimertinib progressed-disease mortality +25%) | 0,662 | Rp 93,4 juta | Rp 141,0 juta |
6. Validasi model
Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0010%).
| Luaran pembanding | Prediksi model | Data terbit | Sumber |
|---|---|---|---|
| Progression-free survival at 12 months, osimertinib arm | 62,5% | 64,4% | FLAURA (Soria et al., NEJM 2018; NCT02296125). Median PFS 18.9 months in the osimertinib arm; 12-month PFS landmark deri |
| Progression-free survival at 12 months, standard-care EGFR-TKI arm | 40,5% | 44,2% | FLAURA (Soria et al., NEJM 2018; NCT02296125). Median PFS 10.2 months in the comparator (gefitinib/erlotinib) arm; 12-mo |
| Overall survival (proportion dead) at 24 months, standard-care EGFR-TKI arm | 28,2% | 41,0% | FLAURA final overall-survival analysis (Ramalingam et al., NEJM 2020; NCT02296125). 24-month OS landmark 59% alive in th |
7. Penyesuaian untuk Indonesia
Uraian berikut tersedia dalam bahasa Inggris.
- EGFR mutation testing availability and turnaround time in Indonesia will affect eligible population and pathway costs.
- BPJS coverage restrictions for first-line osimertinib and biomarker testing must be checked before budget impact use.
- Use Indonesian lung cancer mortality and stage distribution for epidemiology; do not transfer UK incidence directly.
- Scenario analysis should compare osimertinib against afatinib alone, not just gefitinib/erlotinib, because NICE flagged afatinib as likely more effective than first-generation TKIs.